BillionToOne remote jobs and company guide

Through groundbreaking technology, we are revolutionizing molecular diagnostics at BillionToOne. Headquartered in Menlo Park, California, BillionToOne is a precision diagnostics company with a mission to make molecular diagnostics more accurate, efficient, and accessible for all. Our patented Quantitative Counting Templates, or QCTs™, represent a significant technological breakthrough, powering our ability to detect and measure tiny and sparse disease-related DNA fragments at the single base-pair level. This innovation is crucial because several common and severe recessive conditions screened for prenatally can be caused by single-base pair alterations. Our QCT technology enables quantifying these tiny variations using cell-free DNA, opening the door to exponential improvements in prenatal screening, liquid biopsy, and beyond. We believe this quantification will unlock transformative advancements in how diseases are detected and managed. The company's QCT molecular counter platform is the only technology that can count DNA molecules at the single-count level with single base-pair precision, increasing the cell-free DNA diagnostics resolution by over 1,000-fold.

Our innovation focus is evident in our flagship products. UNITY Screen™, our commercially available non-invasive prenatal test (NIPT), is the only NIPT that can assess fetal risk for both recessive conditions (like cystic fibrosis, spinal muscular atrophy, and sickle cell disease) and aneuploidies from a single maternal blood sample, as early as nine weeks into pregnancy, without requiring a paternal sample. This simplifies the testing process and provides timely, precise fetal risk assessments. In 2023, we expanded our innovative approach into oncology with the launch of Northstar™ Select and Northstar™ Response. These pioneering liquid biopsy tests leverage our molecular counting technology for therapy selection and monitoring tumor burden, aiming to transform oncology care. BillionToOne is committed to pushing the boundaries of molecular diagnostics to improve healthcare, with over 500,000 patients having benefited from our precise diagnostic tests. We are dedicated to developing powerful and accurate diagnostic tests that are accessible to all, continually striving to advance healthcare through innovation.